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Thyroid hormones are crucial during development and in the adult brain. Of interest, fluctuations in the levels of thyroid hormones
at various times during development and throughout life can impact on psychiatric disease manifestation and response to treat-
ment. Here we review research on thyroid function assessment in schizophrenia, relating interrelations between the pituitary-thy-
roid axis and major neurosignaling systems involved in schizophrenia’s pathophysiology. These include the serotonergic, dopami-
nergic, glutamatergic, and GABAergic networks, as well as myelination and inflammatory processes. The available evidence sup-
ports that thyroid hormones deregulation is a common feature in schizophrenia and that the implications of thyroid hormones
homeostasis in the fine-tuning of crucial brain networks warrants further research.
1. Introduction
In 1888 a report by the Committee of the Clinical Society
of London explored the association of hypothyroidism with
psychosis [1]. Not surprisingly, given the essential role of thy-
roid hormones for mammalian brain development, the eﬀect
of thyroid hormones (THs) in the modulation of aﬀective
illness and behavior continues to be an avenue of research
in the pathophysiology of mood disorders [2–12]. Com-
plementarily, research has revealed the TH modulation of
crucial brain neurotransmitter systems [12–15] including the
dopaminergic, serotonergic, glutamatergic, and GABAergic
networks [14, 16–20]. As elaborated on throughout this
paper, the misregulation of these pathways, as well as the
participation of myelination and of cytokines, is of particular
relevance in the schizophrenic brain [18, 21–23].
Schizophrenia is one of the most severe psychiatric dis-
orders with an estimated prevalence of 0.7–1.0% in the
population worldwide. It often runs a chronic and debilitat-
ing course, with many patients responding poorly to medi-
cation and suﬀering frequent and disrupting relapses. Fur-
thermore, it is accompanied by a great social cost in terms of
productivity loss and treatment-related expenses [21]. Its
core features include cognitive impairment, delusions, hallu-
cinations, altered volition and emotional reactivity and dis-
organized behavior. It is now clear that the heterogeneity
and complexity of schizophrenia is both at the clinical and
aetiological levels and that this complex disorder arises from
the interaction of a range of deviant genetic traits and envi-
ronmental “insults,” which may begin to act in the prenatal
period [21]. The clear understanding of schizophrenia’s
molecular mechanism(s) is elusive, and no biological marker
has been identified. In eﬀect, a biomarker may be diﬃcult
to find if the disease results from a subtle deregulation in
a biological network with impact on mental health and be-
havior. In this context, modulators of transcriptional activity
and their carriers/receptors are good candidates in bridging
the genetic and environmental determinants of schizophre-
nia. Among these are TH [24].
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Circulating THs, the prohormone thyroxine (T4) and the
active metabolite 3,5,3′-triiodothyronine (T3), are lipophilic
molecules carried by plasma or cerebrospinal fluid (CSF)
proteins. These molecules exert their function mostly via
thyroid receptors that bind T3 with high aﬃnity, acting as
ligand-inducible transcription factors that regulate expres-
sion of T3-responsive genes. Nonetheless, TH may also act
through fast nongenomic actions [25]. The timing and ade-
quate amount of TH’s action is crucial for the normal neuro-
development and maturation of the central nervous system
(CNS) and for proper functioning of the adult brain [6].
Given their described roles, it is not entirely unexpected
that a link between TH and psychiatric disease may be con-
sidered [24, 26]. In the adult, TH fluctuations are associated
with mood alterations, such that changes in TH levels are
common in psychiatric patients across all ages [27–34]. Clin-
ical case reports reveal that hyperthyroid individuals may
manifest psychosis and depression [34–38]. Additionally, the
prevalence of clinical hypothyroidism in psychiatric patients
ranges from 0.5% to 8% [34, 38]. In fact, hypothyroid
patients, or those with hypothyroxinemia, display mood
impairment, as well as decreased motivation and increased
depressive symptoms, such that the prevalence of depressive
symptoms is close to 50% in people with hypothyroidism
[34, 38]. In this regard, studies have evidenced the impact
(correlation) of TH fluctuations in depression, including the
relation between TH levels and depressive-state and treat-
ment outcome and/or response time to treatment [39–50].
“Of notice, TH seem important for the mood improvement”
ability of antidepressants, since about 50% of treatment-
resistant patients become responsive when TH are coadmin-
istered. In particular, T3 administration has been recognized
to hasten recovery [51, 52], although adjunctive supraphys-
iological doses of T4 have proven especially eﬃcacious in
women with unipolar or bipolar disease and refractory to
standard medication [13]. In addition, dementia has been
reported in cases of severe hypothyroidism [34, 38].
In this paper, data on TH circulating levels in cohorts
of schizophrenic patients will be summarized. Also, we will
explore the interplay between TH and main biological net-
works implicated in schizophrenia.
2. Thyroid Hormones and Schizophrenia:
Relationship with Neurotransmitter Systems
and Neural Networks
The link between TH and schizophrenia is pertinent [24, 26,
53]. In point of fact, several groups have measured TH lev-
els, and other thyroid-related parameters, in schizophrenic
patients (hospitalized and outpatients), reporting on several
abnormalities. A compilation of these studies is presented in
Table 1. For the collection of the presented reports the
PubMed database was searched using key terms such as “psy-
chiatric disease,” “schizophrenia,” and “thyroid hormones
[levels],” and/or designation of each thyroid hormone specif-
ically [total and free thyroxine (TT4 and FT4) and triiodo-
thyronine (TT3 and FT3), and thyroid stimulating hormone
(TSH)]. Subsequently, for the generation of the final list,
the PubMed-generated list was cross-referenced with that
derived from the bibliography in articles on schizophrenia
and/or psychiatric disease and TH. From our analysis, to
date, 15 independent studies of human population cohorts
have been published addressing the role of TH in schizo-
phrenic patients, with assessments and/or measurement of
TH status [28, 33, 54–66]. It is of mention that prior to the
mid-1980s the lack of high-sensitivity assays for measure-
ment of TH, specifically for free TH, was a handicap. None-
theless, earlier reports alreadymademention of thyroid func-
tion abnormalities in schizophrenic patients and their fam-
ilies, as well as on the resemblance between the psychotic
symptoms of people with severe hypo- and hyperthyroidism
and those of schizophrenic patients [67–69].
Altogether, from the literature analysis, a dynamic rela-
tionship emerged. For example, a connection between Brief
Psychiatric Rating Scale (BPRS) values, TT4 and FT4 levels
and clinical recovery in male psychiatric patients was re-
ported [58]. Also, a study by Roca and colleagues [60] evi-
denced that 49% of psychiatric patients, in their study pop-
ulation, exhibited significant changes in one or more TH
levels, with a significant positive correlation between severity
of illness and elevations of TH levels. Furthermore, clinical
case reports indicate that hyperthyroid individuals may
manifest psychosis [35–37], a characteristic of the positive
symptoms observed in schizophrenic patients [21], and that
hypothyroid individuals display mood impairment, such as
decreased motivation and increased depressive symptoms,
a presentation similar to the negative symptoms in schizo-
phrenic individuals [21]. Adding to these, unpublished work
from our laboratory indicates that, even within normal
range, FT3 levels in Portuguese schizophrenic male and
female patients were significantly lower when compared to
controls and that FT4 levels were significantly lower in male
patients when compared to mentally healthy individuals
(data presented in meeting proceedings [70]).
Despite diﬃcult interpretation, methodological limita-
tions, and heterogeneity of patients, including complex his-
tory of antipsychotic medication, overall observations indi-
cate that TH level fluctuations may have clinical meaning.
Such observations are pertinent given that the interaction
between the pituitary-thyroid axis and the dopaminergic,
serotonergic, glutamatergic, and GABAergic systems, toge-
ther with any correlation with myelination and proinflam-
matory response, are relevant in schizophrenic patients in
light of their implications in the etiology of the disease [14,
16–20, 22, 23, 71]. In the schizophrenia context, each of these
neural networks will be next addressed.
2.1. Dopaminergic System. Dopamine was the first neuro-
chemical to be associated with schizophrenia, in part due to
the eﬃcacy of antipsychotic drugs that block dopamine D2-
like receptor in alleviating the hallucinations and delusions
of patients (review [19]). Additionally, neuroimaging studies
have revealed enhanced activity of the nigrostriatal dopamine
system, albeit a hypofunctionality of the mesoprefrontal
cortical system, in schizophrenic individuals [72, 73].
Thyroid hormones have been shown to regulate the
levels of dopamine receptors [74, 75] and the activity of
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tyrosine hydroxylase [76–78], the rate-limiting enzyme of the
cathecolaminergic pathway. Moreover, it has been suggested
that dopamine may be inhibitory of TSH secretion [59], as
treatment with dopamine blockers lead to increase in TSH
level or to subclinical hypothyroidism [79], and that hypo-
thyroidism can lead to increased dopamine receptor sensitiv-
ity [74]. In a human study of acutely ill schizophrenic pa-
tients, Rao et al. [55] analyzed the interrelation between
serum levels of dopamine, prolactin, TSH, and T4. The serum
levels of dopamine were found to be elevated in schizo-
phrenic patients, while levels of the other parameters were
decreased. The increased dopaminergic activity was hypothe-
sized to aﬀect the pituitary secretory function, and decreased
beta-adrenergic activity was inferred as consequence of dec-
reased serumTSH concentration. This is of further interest as
α1- and β-adrenergic catecholamines are involved in main-
taining deiodinase activity, and thus brain thyroid status
[80]. As such, type-1 deiodinase impairment may result in
a drop in T3 levels, with unchanged T4, and type 2 or 3
deiodinase impairment may be reflected in decreased T4
metabolization.
2.2. Serotonergic System. Serotonin (5-hydroxytryptamine,
5-HT) is an essential neurotransmitter. Curiously, it was first
thought to have a role in schizophrenia given its similarity to
lysergic acid diethylamide (LSD), a compound that competes
for and occupies serotonin’s receptor sites, resulting in psy-
chotic symptoms [81]. Since then, perhaps the strongest
evidence of serotonin’s involvement in schizophrenia is the
role that its receptors play in the mechanism of atypical
antipsychotic drugs which, besides their high receptor selec-
tivity, show a weak direct dopaminergic antagonist eﬀect
[82]. According to the current view, serotonergic signaling
may have amodulatory influence on central dopamine trans-
mission, which may significantly contribute to the ther-
apeutic eﬀects of atypical antipsychotics [83]. Altogether,
observations led to a serotonin hypothesis of schizophrenia.
Enhanced serotonergic signaling, especially via serotonin
type 2A receptors, is thought to be involved in the pathology
of schizophrenia specifically during the early phases of psy-
choses ([84] and review [20]). On the other hand, deficient
central 5-HT functions may underlie some of the negative
symptoms in schizophrenic patients [83, 85].
Establishing a link between the serotonergic system and
TH modulation, Strawn et al. [86] measured CSF concen-
trations of 5-hydroxyindoleacetic acid (5-HIAA) and homo-
vanillic acid (HVA), major metabolites of serotonin and
dopamine, as well as plasma concentrations of various THs.
The concentration of 5-HIAA was significantly and nega-
tively correlated with plasma TSH and TT3, while that of
HVA was significantly and negatively correlated with plasma
TSH, TT3, and FT3. Such findings, indicative of monoamine-
thyroid interactions, are significant as studies have shown
diminished 5-HT activity in hypothyroid patients [87, 88]
and a negative correlation between TSH and CSF concentra-
tions of 5-HIAA in patients with unipolar depression [89].
Of note, in a separate population of patients diagnosed with
major depressive disorder, no correlation was found bet-
ween TSH and 5-HIAA [90]. Nonetheless, as reviewed by
Bauer et al. [13], most human studies in hypothyroid pa-
tients evidence a reduced 5-HT responsiveness, that is, rever-
sible with TH replacement therapy. Furthermore, studies in
hypothyroid-state-induced animals showed that 5-HT turn-
over is increased in the brainstem and that its levels, as well
as those of its precursors, are decreased in the cortex/whole
brain [91–94]. Also, reports indicate an increase in cortical
5-HT concentrations and desensitization (no change in den-
sity) of autoinhibitory 5-HT1A receptors in the raphe area,
resulting in disinhibition of cortical and hippocampal 5-HT
release, and in increased cortical 5-HT2 receptor sensitivity
[95–97]. Altogether, there is evidence that thyroid status
impacts the serotonin system in the adult brain and vice versa
[13].
2.3. Glutamatergic System. The glutamatergic hypothesis of
schizophrenia is based upon the observation that psycho-
tomimetic agents, such as ketamine and phencyclidine, in-
duce neurocognitive deficiencies and psychotic symptoms,
similar to those of schizophrenia, through blockage of the
neurotransmission at N-methyl-D-aspartate-(NMDA-) type
glutamate receptors [98]. Given that the glutamate/NMDA
receptors are ubiquitously distributed in the brain, gluta-
matergic models of schizophrenia predict widespread corti-
cal dysfunction, in particular hypofunctionality of the fore-
brain glutamate system (review [16, 99]). Furthermore, sup-
porting the model in which reduced NMDA receptor activity
may result in schizophrenic-like behavior, animal data have
shown that mice expressing only 5% of normal levels of the
NMDAR1 receptor subunit display behavioral abnormalities
similar to those observed in pharmacologically induced ani-
mal models of schizophrenia [100]. The phenotype can be
ameliorated by treatment with antipsychotic drugs (dopa-
minergic and serotonergic receptors antagonists). Altogether,
the literature corroborates a link between the glutamatergic-
and dopaminergic-based systems, particularly considering
that the NMDA receptors are colocated on brain circuits that
regulate dopamine release [99].
Mendes-de-Aguiar et al. [15] studied the role of T3 in
the CNS, specifically on regulation of glutamate uptake. The
team showed an increased neuronal viability against tox-
icity when neurons were cultured in the presence of T3-
treated astrocytes. Altogether, the authors concluded that
T3 is capable of regulating extracellular glutamate levels by
modulating the astrocytic glutamate transporters and, con-
sequently, by promoting neuronal development and neuro-
protection. In another study, male rats were treated with glu-
tamate receptor agonists and antagonists and serum TH
levels were assessed [101]. The results indicated that agonist
administration increased TSH concentrations, while antag-
onists decreased TSH and TH serum levels, indicating that
endogenous excitatory amino acids may play a part in the
regulation of TH secretion [102]. These studies are in agree-
ment with reports on glutamate and other endogenous exci-
tatory amino acids, such as L-aspartate, N-methyl-D-aspar-
tate, kainate, and amino-hydroxy-5-methyl-4-isoxazole pro-
pionate, in their ability to regulate the secretion of anterior
pituitary hormones as well as in the neuroendocrine regula-
tion of the hypothalamic-pituitary axis (review [103]).
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2.4. GABAergic System. The role for the GABA (δ-amino-
butyric acid)-ergic system in the pathogenesis of schizophre-
nia derives mostly from neuropathologic studies [104]. Spe-
cifically, the chandelier neurons, a subtype of GABA inter-
neurons, have decreased immunostaining for the GABA
transporter, possibly related to decreased BDNF signaling
or NMDA receptor hypofunction. Furthermore, upregula-
tion of the postsynaptic GABA-A receptors, together with
reduction of both glutamic acid decarboxylase (GAD) 67
and reelin (a protein that colocalizes with GABAergic inter-
neurons), was described in schizophrenic patients [105].
GAD67 and reelin are involved in the glutamate conversion
to GABA and in synaptic plasticity and/or neuromigration.
The possibility that TH aﬀects the GABAergic system
was first putforward in the 1960s and since then multiple
studies have examined various aspects of this relationship,
altogether suggesting that some human nervous disorders
involving GABAergic systems are related to thyroid dysfunc-
tion. Overall, as expertly reviewed by Wiens and Trudeau
[14], the eﬀect of TH on the GABAergic system can
take place at multiple levels, including circuit formation,
enzymes involved in synthesis and metabolism of GABA and
glutamate, GABA release and reuptake, and GABA receptors.
For example, in rat models, thyroidal status has been
shown to influence the development of inhibitory cortical
GABAergic circuits [106]. Also, neonatal hypothyroidism
was evidenced to result in decreased GAD activity in various
brain regions of the neonate brain [107, 108], although not
in the adult brain. In addition, T3 administration was shown
to accelerate the developmental increase in GAD activity in
both in vivo and in vitro models [109, 110]. Furthermore,
other studies revealed lower activity of two other enzymes
in GABA metabolism, GABA aminotransferase and succinic
semialdehyde dehydrogenase, in hypothyroid animals [111],
and that T3 replacement restored activity back to control
levels [112]. At the GABA concentration level, neonatal rats
rendered hypothyroid have reduced whole brain glutamate
and GABA concentrations, from within 2 hours of birth to
postnatal day 30 [113]; interestingly, levels were not found to
be increased in animals rendered hyperthyroid [114]. In con-
trast, whole glutamate and GABA levels were found elevated
in hypothyroid animals [115] (rendered hypothyroid when
adults) and, in accordance, with the increase GAD activity
also noted. These observations point for the possible diverse
influence of TH depending on the developmental stage. Data
for animals rendered hyperthyroid are discordant between
studies. Overall, evidence continues to indicate a correla-
tion, although a positive correlation between TH levels and
GABAergic function in the developing brain and a negative
correlation in adult animals is not always a consistent finding
[14]. Adding to these observations, studies indicate that TH
aﬀects GABA release and reuptake. For example, in in vitro
preparations of synaptosomes, from adult rat cerebral cortex,
low concentration of T3, but not of T4 or rT3, increased depo-
larization-induced GABA release by a direct nongenomic
mechanism [116]. At the GABA receptor level, studies
indicate that TH have direct nongenomic eﬀects on the
GABAA receptor complex, specifically that, in the presence
of GABA, T3 inhibits GABA-stimulated Cl− currents in rat
forebrain membranes and in its absence it induces the Cl−
current [117, 118]. On the other hand, GABA can aﬀect TH
function; GABA can inhibit TSH-stimulated TH release from
the thyroid gland and aﬀect TSH secretion from the pituitary.
On the role of adequate functioning of the maternal thy-
roid gland in oﬀspring thyroid status development, the
report by Ahmed et al. [119], on hypo-/hyperthyroidism ani-
mal models in dams, is especially noteworthy regarding the
TH-GABAergic system interplay. The study revealed that
maternal hypothyroidism induced decreases in both mono-
amine levels and in acetylcholinesterase activity and increases
in the GABA content of the oﬀspring. This was accompanied
by suppression of Na+, K+-ATPase, Ca2+-ATPase, and Mg2+-
ATPase activity in diﬀerent brain regions. On the other hand,
maternal hyperthyroidism produced reverse eﬀects. The
authors concluded that maternal hypothyroidism and hyper-
thyroidism might induce inhibitory and stimulatory eﬀects,
respectively, on the excitability and synaptic neurotransmis-
sions in the progeny’s brain [119].
2.5. Myelination and Cytokines. The TH involvement in the
regulation of myelination and/or oligodendrocytes’ functio-
nality, central processes in the modulation of neural net-
works, is of interest in schizophrenia, where involvement of
white matter has been implicated [22, 71, 120–123].
Associations between TH levels and myelination have
been reported. Hypothyroidism is associated with delayed
myelination in several brain regions [124, 125]. Further-
more, myelin-related genes, shown to be downregulated in
postmortem schizophrenic brain, including cyclic nucleotide
phosphodiesterase, myelin-associated glycoprotein, transfer-
ring, and v-erb-b2 erythroblastic leukemia viral oncogene
homolog 3 [122], are regulated by TH. Also, changes ob-
served in the identified cell cycle genes, frommicroarray ana-
lysis of schizophrenic patients [123], are particularly inter-
esting given that two genes, cyclin D1 and cyclin-dependent
kinase inhibitor 1C (P57), central to oligodendrocyte diﬀer-
entiation, have been shown to be among the early regulated
cell cycle genes after exposure to TH, a “cue” essential to
trigger oligodendrocyte diﬀerentiation [126, 127].
Myelin abnormalities in the neurological/psychiatric-
diseased brain are often presented with an inflammatory
component. In schizophrenia, evidence from clinical data
supports a potential pathogenic role of elevated cytokine
expression. Both childhood and adult schizophrenia are
characterized by elevated expression of IL-1, IL-6, and TNF-
α in the CSF, along with altered cytokine or cytokine receptor
expression [23, 128]. While many cytokines may be virtually
undetectable in a healthy noninflamed system, their induc-
tion (abnormal or in a response to an inflammatory trigger)
in immune and glial cells, such as astrocytes and microglia,
may play a significant role in the deregulation of neural cell
homeostasis, with vast consequences at the level of oligoden-
drocyte function and myelination (review [71]). In this line,
it is relevant to mention that whereas THs play an important
role in the regulation of deiodinases activity under normal
metabolic conditions, other regulating mechanisms might
be involved in TH metabolism during pathophysiological
conditions, which may overlap with those known to be
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relevant for the development of schizophrenia. During these
conditions, a state of altered THmetabolism can occur [non-
thyroidal illness (NTI)], which is characterized by a fall of
serum T3 [129, 130], due to decreased extrathyroidal conver-
sion of T4 into T3 by type 1 deiodinase, without an increase
in serum TSH [131, 132]. In these studies, TRβ1 has been
found to be downregulated (in an animal model of NTI), and
type 3 deiodinase activity shown to be upregulated in liver
and skeletal muscle of critically ill patients. Correspondingly,
what renders these observations of particular interest, in the
schizophrenia-TH-inflammation interrelation, is that in sites
of local inflammation, induced in animal models by site-
directed bacterial endotoxin (lipopolysaccharide) adminis-
tration, deiodinase type 3 activity in inflammatory cells is
strongly induced, suggesting enhanced local degradation of
T3 [132].
2.6. Thyroid Hormones as Neurotransmitters. The role of TH
in the pathophysiology of schizophrenia is more so note-
worthy when considering the possible function of TH as
neurotransmitters. The breakthrough hypothesis of a neuro-
transmitter role for T3 was put forward in the endocrinology
field in the 1970s by Dratman and collaborators [133], based
on the colocalization of TH with the noradrenergic system
[134]. Given the vast roles of T3 in the brain, this is hardly
unexpected. Among others, T3 promotes diﬀerentiation in
astrocytes, mediates cerebellar astrocyte and neuronal prolif-
eration, and participates in the organization of extracellular
matrix molecules via astrocytes [15, 135]. Recently, Scanlan
and team (review [136]) have explored a similar neuro-
transmitter function for 3-iodothyronamine (T(1)AM), a
molecule proposed to result from a unique biosynthetic deio-
dination pathway starting from the decarboxylation products
of either T4 or rT3. The hormone T3 is reported to accu-
mulate in nerve endings reaching high concentrations in
the synaptosome [137, 138] and being released from it
in a Ca2+-dependent mechanism [139]. In in vitro studies
T1AM has been found to block the transporters for the
amines/neurotransmitters dopamine, norepinephrine, and
serotonin. Interestingly, T1AM binds with high aﬃnity to the
trace-amine-associated receptor (TAAR) [136, 140], a class
of G-protein-coupled receptors, and genetic linkage studies
have shown a significant association between the TAAR gene
and susceptibility to schizophrenia [141].
3. Thyroid Hormones and Schizophrenia:
Human Studies Considerations
Thyroid hormones are widely distributed in the brain, with
a multitude of eﬀects on the CNS including a putative eﬀect
in the pathogenesis of psychiatric disorders. Indicating this
interrelation, the successful treatment of aﬀective disorders
often includes the coadministration of TH. Despite these
observations, the molecular action(s) that may underlie the
mood-modulating properties of TH in the adult brain has
only fairly recently become of greater interest. As such, when
reporting on this type of analysis, three main aspects are of
essence for the neuropsychiatric community to incorporate
and/or consider in current and future studies: (i) the eﬀect
of antipsychotic medication, (ii) determination of CSF levels
of TH, and (iii) the introduction of longitudinal studies of
prenatal, neonatal, and/or childhood TH status, related to
propensity to develop schizophrenia at the adult age, parti-
cularly in at-risk oﬀspring (e.g., familial history of schizo-
phrenia), as well as familial TH level correlations. These will
next be summarily discussed.
3.1. Eﬀect of Antipsychotic Medication on Thyroid Hormone
Status. The literature reports on the eﬀect of neuroleptic
medication on deiodinases activities, as well as on the N-glu-
curonidation of TH, and by consequence on TH levels.
Namely, the commonly used antipsychotic haloperidol can
enhance type 2 deiodinase, while clozapine decreases type 2
but increases type 3 deiodinase activity in several brain re-
gions [142]. In addition, some antipsychotics, such as cloza-
pine, are piperazine-containing drugs that undergo N-glucu-
ronidation. Given that the enzyme UDP-glucuronosyltrans-
ferase is responsible for the glucuronidation of TH and of
certain psychotropic medications [143], a competitive mech-
anism may be conducive to TH level changes [65]. Finally,
it may also be worthy of consideration that, even in cases
where no change in circulating levels of TH is observed, dere-
gulated deiodinase activity may aﬀect the spatiotemporal
distribution and local regulation of TH [144, 145].
3.2. Serum and CSF Thyroid Hormone Level Assessments. The
measurement of TH levels in CSF samples would be more
likely to represent TH brain homeostasis. Not only would
this type of analysis add to ones already done to identify
schizophrenia disease markers (e.g., [146] and review [147]),
but it would also fill in a gap regarding the measurement of
TH levels in the CSF of schizophrenic patients as such study is
lacking in the field. This could be done in amanner similar to
a study in an Alzheimer’s disease population, which revealed
rT3 level alterations in the CSF that were not reflected in the
sera samples [148].
3.3. Familial, PreNatal, Neonate, and Early Childhood Thyroid
Status. During development TH play a crucial role in CNS
development, including in cerebral cytoarchitecture, neural
growth, and synaptogenesis [149–151]. Consequently, it fol-
lows that the thyroid status and timing during development,
including neonatal, has a significant impact on behavior,
locomotor ability, speech, and cognition [2–8, 152]. Further-
more, given that the fetus relies on the mother for the ade-
quate supply for TH, it is relevant to consider maternal thy-
roid status during pregnancy; for example, maternal hypo-
thyroxinemia leads to decreased T4 availability for the fetal
brain, that is, associated with neuropsychological impair-
ments of the child [153]. Neurodevelopment can be restored
to within the normal range upon TH supplementation in
case of neonatal hypothyroidism [154], although subtle ab-
normalities remain in these children. Such observations are
further correlated with animal work findings that indicate
how TH status, even prenatally, may impact on neuronal
excitability and synaptic transmission within the CNS [119].
Altogether, TH status seems relevant in the pre- and post-
natal periods, and there are critical periods during which
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diﬀerent parts of the brain and/or aspects of the CNS deve-
lopment are sensitive to TH supply [155]. Thus, to further
understand the impact of TH on behavior, it would be of
interest not only to investigate TH status in adulthood in
mood and cognitive disorders, but also how alterations in the
hormonal milieu during development might impact on adult
behavior (as has been recently shown to be case for other
hormones, such as glucocorticoids [156, 157]). In this regard,
it would be further interesting to broaden thyroid assessment
studies to include mentally healthy siblings of schizophrenia
patients.
4. Conclusions
Thyroid hormone assessment in schizophrenic patients pre-
sents a particular challenge. Often, the heterogeneity of
patients, including many with a complex history of antipsy-
chotic medication, renders impossible a “clean” TH basal
determination in disease state. Deregulations of the pitui-
tary-TH axis continue to be of interest given the interaction
between the pituitary-thyroid axis and the dopaminergic,
serotonergic, glutamatergic, and GABAergic systems, toge-
ther with relationships with myelination and proinflamma-
tory response, which are strongly implicated in schizophre-
nia. The fine-tuning of these networks and their precise imp-
lication on disease etiology certainly warrants further inves-
tigation.
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